


Express Mail Label No.: EV054296652US  
Date of Deposit: February 11, 2002

Attorney Docket No. 21402-135



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Bader  
SERIAL NO.: 09/966,870 EXAMINER: Not Yet Assigned  
FILING DATE: September 28, 2001 ART UNIT: 1645  
FOR: Method of Identifying Genetic Regions Associated with Disease and Predicting  
Responsiveness to Therapeutic Agents

**Box IDS**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant hereby makes of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 21402-135.

Respectfully submitted,



Ivor R. Efron, (Reg. No. 39,529)

Attorney for Applicant

c/o MINTZ, LEVIN, COHN, FERRIS

GLOVSKY AND POPEO, P.C.

One Financial Center


Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: February 11, 2002

TRA 1628371v1



Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/966,870
	<b>Filing Date</b>	09/28/2001
	<b>First Named Inventor</b>	Bader
	<b>Group Art Unit</b>	1645
	<b>Examiner Name</b>	Not Yet Assigned
	<b>Attorney Docket Number</b>	21402-135

**U.S. PATENT DOCUMENTS**

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**


Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Chong, et al. (2000). "Influence of genetic polymorphisms in the beta2-adrenoceptor on desensitization in human lung mast cells." <i>Pharmacogenetics</i> 10(2): 153-162.
	C2	Drysdale, et al. (2000). "Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness." <i>Proc. Natl. Acad. Sci. USA</i> 97(19): 10483-10488.
	C3	Liggett (2000). "The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma." <i>J. Allergy. Clin. Immunol.</i> 105(2 Pt 2): S487-492.
	C4	Long and Langley (1999). "The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits." <i>Genome Res.</i> 9(8): 720-731.
	C5	MacLean, et al. (2000). "The trimmed-haplotype test for linkage disequilibrium." <i>Am. J. Hum. Genet.</i> 66(3): 1062-1075.
	C6	McGraw, et al. (1998). "Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression." <i>J. Clin. Invest.</i> 102(11): 1927-1932.
	C7	Tan, et al. (1997). "Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics." <i>Lancet</i> 350(9083): 995-999.
	C8	Taylor, et al. (2000). "Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism." <i>Thorax</i> 55(9): 762-767.
	C9	Terwilliger and Ott (1992). "A haplotype-based 'haplotype relative risk' approach to detecting allelic associations." <i>Hum. Hered.</i> 42(6): 337-346.

copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Owner's Signature		Date Considered	
-------------------	--	-----------------	--

NOTE: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) in this box



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/966,870
	<b>Filing Date</b>	09/28/2001
	<b>First Named Inventor</b>	Bader
	<b>Group Art Unit</b>	1645
	<b>Examiner Name</b>	Not Yet Assigned
	<b>Attorney Docket Number</b>	21402-135

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Chong, et al. (2000). "Influence of genetic polymorphisms in the beta2-adrenoceptor on desensitization in human lung mast cells." <i>Pharmacogenetics</i> 10(2): 153-162.
	C2	Drysdale, et al. (2000). "Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness." <i>Proc. Natl. Acad. Sci. USA</i> 97(19): 10483-10488.
	C3	Liggett (2000). "The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma." <i>J. Allergy. Clin. Immunol.</i> 105(2 Pt 2): S487-492.
	C4	Long and Langley (1999). "The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits." <i>Genome Res.</i> 9(8): 720-731.
	C5	MacLean, et al. (2000). "The trimmed-haplotype test for linkage disequilibrium." <i>Am. J. Hum. Genet.</i> 66(3): 1062-1075.
	C6	McGraw, et al. (1998). "Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression." <i>J. Clin. Invest.</i> 102(11): 1927-1932.
	C7	Tan, et al. (1997). "Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics." <i>Lancet</i> 350(9083): 995-999.
	C8	Taylor, et al. (2000). "Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism." <i>Thorax</i> 55(9): 762-767.
	C9	Terwilliger and Ott (1992). "A haplotype-based 'haplotype relative risk' approach to detecting allelic associations." <i>Hum. Hered.</i> 42(6): 337-346.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.